Nearly the entire safety record for the human growth hormone C-terminal fragment comes from one engineered analogue, AOD-9604, and not from the raw 176-191 sequence sold as a research peptide. In supervised trials that analogue was well tolerated over weeks to a few months, showed no rise in serum IGF-1, and produced none of the metabolic harms of full-length growth hormone, though that is a short-term, human-clinical finding on an analogue rather than proof the peptide as used is safe. No medicines regulator has approved either form, and there is no controlled human safety data at all on the unmodified fragment.
Short-term tolerability data exists only for the AOD-9604 analogue across roughly 900 participants over weeks to months, while the unmodified 176-191 fragment has no controlled human safety data and neither form holds any marketing authorisation.
The recorded adverse-event profile was undramatic and overlapped heavily with placebo. A pooled review of six phase 1 and phase 2 trials, on the order of 900 participants with dosing that reached twelve and in one study twenty-four weeks, logged mostly low-grade events and no serious adverse events that investigators attributed to the drug. This is human-clinical evidence, but from a database frozen small when the programme stopped for weak efficacy.
The pooled trial database recorded no serious adverse events attributed to the drug and no anti-AOD-9604 antibodies, with headache the most common complaint at rates comparable to placebo.
On the metabolic axis the fragment did not behave like full-length growth hormone in the reported trials, which is the single most informative negative finding in the dataset. Full-length growth hormone drives hepatic glucose output, antagonises insulin, and raises IGF-1, while the C-terminal region lacks the receptor-binding surfaces for that signalling and left glucose handling and IGF-1 unchanged over the weeks studied. That reassurance is bounded: the measurements were short, taken in relatively healthy obese adults, and say nothing about chronic use or interaction with glucose-lowering drugs.
| Metabolic axis | Full-length growth hormone | C-terminal fragment (AOD-9604) |
|---|---|---|
| Serum IGF-1 | Raised via hepatic production | No rise above baseline |
| Insulin sensitivity | Worsened, antagonises insulin signalling | No deterioration vs placebo |
| Glucose tolerance | Impaired, can drive new-onset diabetes | Unchanged over short trials |
| Evidence horizon | Decades of prescribed use | Weeks, healthy obese adults only |
Across the reported trials serum IGF-1 stayed at baseline and glucose tolerance and insulin sensitivity did not deteriorate relative to placebo, but only over weeks in healthy obese adults, not under chronic use or alongside glucose-lowering therapy.
No proliferation or carcinogenicity signal has been reported in the preclinical record, and the studies capable of detecting a slow one were never run. Rodent work in obese and diabetic models showed reduced body fat without the somatic growth, organomegaly, or skeletal change of growth hormone, which is coherent with a compound that does not raise IGF-1 or meaningfully engage the growth hormone receptor. The proliferation question stays open because a complete carcinogenicity package was never assembled.
No proliferation or carcinogenicity signal has been reported in the available in vitro and rodent work, but no two-year bioassay, full genotoxicity battery, or long-term non-rodent study was ever completed to detect a slow one.
A trial only detects what its design gives it the chance to see, and on both duration and size this record is thin. The longest documented continuous human exposure runs to a few months, so any harm with a latency of years sits outside the observation window, and roughly 900 participants can exclude common harms while missing uncommon ones entirely. The programme also stopped for weak efficacy, not because a long-term safety question was ever resolved.
A database of roughly 900 participants dosed for at most a few months can confidently exclude common harms but cannot detect events rarer than about one in a thousand, which would require on the order of 3,000 exposures.
For a peptide obtained outside a prescription pathway, product-quality risk is separable from molecular risk and may be the larger of the two. Independent testing of research-chemical peptides has repeatedly found contents at odds with the label, and the not-for-human-consumption wording is why the material sits outside pharmaceutical manufacturing rules entirely. Handling hazards then stack on top once a vial is open.
Peptides sold as research chemicals carry no pharmacopoeial identity, sterility, or endotoxin specification, and independent testing has repeatedly found underdosing, wrong or truncated sequences, and bacterial endotoxin capable of causing fever and inflammatory reactions on injection.
No medicines regulator anywhere has approved this fragment or its analogue for any indication, so no complete safety and efficacy dossier has ever been reviewed and cleared. The recurring finding is insufficient characterisation of the safety profile rather than a catalogue of documented injuries, which is the crux: the position is unproven safety, not proven danger. Anti-doping and food-ingredient designations are separate tracks that establish nothing about therapeutic injectable safety.
| Criterion | US FDA | WADA | Australia TGA |
|---|---|---|---|
| Approval status | No authorisation; withdrawn from compounding nomination | No drug approval | Not on the register of therapeutic goods |
| Stated basis | Immunogenicity, impurity, limited safety data | Growth-factor class, precaution | No completed review |
| Nature of finding | Unproven safety | Fairness and health precaution | Never assessed |
No medicines regulator in the United States, Australia, the United Kingdom, or European Union has granted marketing authorisation, and the FDA's stated position is insufficiently characterised safety rather than documented danger, while WADA prohibits the substance at all times.
The caution here is driven by the shape of the evidence gap, not by observed harm, and the groups that warrant it most are precisely the ones every trial excluded. Each caveat below is a statement that the relevant study has not been done rather than a report of injury. Combination use is the largest practical risk multiplier.
The populations warranting the most caution, cancer survivors, pregnant and breastfeeding women, under-18s, and people with diabetes, are exactly those excluded from every trial, so no direct safety data covers them.
Recombinant growth hormone has a well-mapped adverse-effect profile from decades of prescribed use, while the fragment's trials specifically monitored the effects most likely to appear and did not find them. The structural reason is that the C-terminal region lacks the binding domains that dimerise the growth hormone receptor, so IGF-1 production and somatic growth have no mechanism to occur. The honest reading is a weaker signal in both directions, not a proven safety advantage, since the two evidence bases are nowhere near comparable in depth.
| Effect domain | Recombinant growth hormone | C-terminal fragment |
|---|---|---|
| Fluid retention and oedema | Common | Not observed |
| Glucose tolerance | Worsened, can trigger diabetes | Unchanged in trials |
| IGF-1 and acromegalic change | Raised, coarse acral change with excess | No IGF-1 rise, none reported |
| Evidence depth | Millions of patient-years | A few hundred people over months |
The fragment analogue showed none of growth hormone's IGF-1 elevation, fluid retention, or glucose deterioration in trials, but its few hundred participant-months cannot support a like-for-like safety claim against growth hormone's millions of prescribed patient-years.
The gaps are easier to list than the findings: no controlled human trial of the unmodified 176-191 fragment, no exposure beyond a few months, no completed carcinogenicity or reproductive package, and no data in cancer survivors, diabetics, pregnancy, or minors. Closing them would take the ordinary apparatus of drug development, none of which is underway, and without an approved product no pharmacovigilance stream captures a harm occurring today. The documented clinical posture for anyone using the substance is to make the use visible rather than hidden.
The unmodified 176-191 fragment has no controlled human trial, no exposure beyond a few months, and no completed carcinogenicity or reproductive toxicology, and with no approved product there is no pharmacovigilance stream to record a harm occurring today.
Educational use only. This article describes what the published scientific and clinical literature reports about HGH Fragment 176-191. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
